Jo Howard

List of Publications by Year in descending order

40 papers	2,165 citations	430874 18 h-index	289244 40 g-index
43 all docs	43 docs citations	43 times ranked	1664 citing authors

#	Article	IF	Citations
1	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519.	27.0	401
2	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Advances, 2020, 4, 327-355.	5.2	241
3	The obstetric management of sickle cell disease. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 25-36.	2.8	236
4	The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet, The, 2013, 381, 930-938.	13.7	209
5	Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood, 2015, 125, 3316-3325.	1.4	167
6	Guideline on the management of acute chest syndrome in sickle cell disease. British Journal of Haematology, 2015, 169, 492-505.	2.5	138
7	Sickle cell disease: when and how to transfuse. Hematology American Society of Hematology Education Program, 2016, 2016, 625-631.	2.5	104
8	A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood, 2019, 133, 1865-1875.	1.4	84
9	Pregnancy outcome in patients with sickle cell disease in the <scp>UK</scp> â€“ a national cohort study comparing sickle cell anaemia (<scp>H</scp>b<scp>SS</scp>) with <scp>H</scp>b<scp>SC</scp> disease. British Journal of Haematology, 2015, 169, 129-137.	2.5	83
10	Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology,the, 2021, 8, e323-e333.	4.6	61
11	Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease. British Journal of Haematology, 2018, 181, 460-475.	2.5	59
12	Hyperhemolysis in Patients With Hemoglobinopathies: A Single-Center Experience and Review of the Literature. Transfusion Medicine Reviews, 2015, 29, 220-230.	2.0	46
13	How I treat the older adult with sickle cell disease. Blood, 2018, 132, 1750-1760.	1.4	31
14	Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline. British Journal of Haematology, 2021, 194, 980-995.	2.5	28
15	A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation. Thrombosis Research, 2014, 133, 190-195.	1.7	27
16	<scp>PF</scp>â€04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placeboâ€Controlled Study. Clinical and Translational Science, 2019, 12, 180-188.	3.1	25
17	How I manage red cell transfusions in patients with sickle cell disease. British Journal of Haematology, 2018, 180, 607-617.	2.5	23
18	A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study of PF-04447943 in Patients with Stable Sickle Cell Disease: Changes in Exploratory Biomarkers. Blood, 2017, 130, 974-974.	1.4	23

#	Article	IF	Citations
19	Cementless Total HIP Replacements in Sickle Cell Disease. HIP International, 2016, 26, 186-192.	1.7	19
20	Prevalence of Nocturnal Hypoxia and Its Association with Disease Severity in Adults with Sickle Cell Disease.. Blood, 2009, 114, 261-261.	1.4	16
21	Biopsychosocial Predictors of Quality of Life in Paediatric Patients With Sickle Cell Disease. Frontiers in Psychology, 2021, 12, 681137.	2.1	13
22	Outcomes following kidney transplantation in patients with sickle cell disease: The impact of automated exchange blood transfusion. PLoS ONE, 2020, 15, e0236998.	2.5	12
23	Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial. Trials, 2020, 21, 347.	1.6	12
24	Pain management and quality of life in sickle cell disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 347-352.	1.4	11
25	Low flow nocturnal oxygen therapy does not suppress haemoglobin levels or increase painful crises in sickle cell disease. British Journal of Haematology, 2013, 161, 455-456.	2.5	10
26	Costâ€effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the <scp>TAPS</scp> trial. European Journal of Haematology, 2014, 92, 249-255.	2.2	10
27	Prevention of Morbidity in sickle cell disease - qualitative outcomes, pain and quality of life in a randomised cross-over pilot trial of overnight supplementary oxygen and auto-adjusting continuous positive airways pressure (POMS2a): study protocol for a randomised controlled trial. Trials, 2015, 16, 376.	1.6	10
28	Measurement of Disease Severity in Patients with Sickle Cell Disease: A Systematic Review.. Blood, 2007, 110, 2250-2250.	1.4	9
29	Prevention of Morbidity in Sickle Cell Disease (POMS2a)â€"overnight auto-adjusting continuous positive airway pressure compared with nocturnal oxygen therapy: a randomised crossover pilot study examining patient preference and safety in adults and children. Trials, 2019, 20, 442.	1.6	8
30	The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease. Thrombosis Research, 2017, 158, 113-120.	1.7	6
31	Maternal sickle cell disease and twin pregnancy: a case series and review of the literature. Hematology, 2019, 24, 148-158.	1.5	6
32	Perinatal outcomes in women with sickle cell disease: a matched cohort study from London, UK. British Journal of Haematology, 2022, 196, 1069-1075.	2.5	6
33	Mildly raised tricuspid regurgitant velocity 2.5â€“3.0â€‰m/s in pregnant women with sickle cell disease is not associated with poor obstetric outcome â€“ An observational cross-sectional study. Obstetric Medicine, 2016, 9, 160-163.	1.1	5
34	Sickle Cell/Î²0-Thalassemia Associated With the 1393 bp Deletion Can be Associated With a Severe Phenotype. Hemoglobin, 2011, 35, 406-410.	0.8	4
35	An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE). Blood, 2020, 136, 19-20.	1.4	4
36	Sickle cell disease in pregnancy. Obstetrics, Gynaecology and Reproductive Medicine, 2012, 22, 254-263.	0.3	3

#	Article	IF	Citations
37	Evaluation of the validity of Hb A2and mean corpuscular haemoglobin action values in antenatal screening for beta thalassaemia carriers in England. British Journal of Haematology, 2014, 166, 607-611.	2.5	2
38	Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients. Blood, 2020, 136, 29-30.	1.4	1
39	Expanded eligibility for emerging therapies in sickle cell disease in the <scp>UK</scp> â€“ crizanlizumab and voxelotor. British Journal of Haematology, 2022, , .	2.5	1
40	Acute painful sickle cell crisis. , 0, , 601-604.		0